Document:

EXHIBIT 10.15

[ON THE GO LETTERHEAD]

On the Go Healthcare, Inc.
85 Corstate Avenue, Unit 1
Concord, Ontario
Canada L4K 4Y2

March 9, 2007

Douglas Leighton
Dutchess Private Equities Fund, Ltd.
50 Commonwealth Avenue, Suite 2
Boston, MA 02116

Subject: Side Letter Agreement to the Investment Agreement between On the Go
Healthcare, Inc. and Dutchess Private Equities Fund, Ltd., dated
January 16, 2007.

Dear Mr. Leighton:

This Side Letter Agreement entered into on March 9, 2007, by and between
On the Go Healthcare, Inc. (the "Company") and Dutchess Private Equities
Fund, Ltd. will serve to modify Section 2(G) of the Investment Agreement
(the "Agreement") entered into on January 16, 2007, by and between On the
Go Healthcare, Inc. and Dutchess Private Equities Fund, Ltd.  Capitalized
terms used herein which are not otherwise defined shall have the same
meaning as those given to them in the Agreement.

Section 2(G) of the Agreement is hereby modified as follows:

(G) MECHANICS OF PURCHASE OF SHARES BY INVESTOR. Subject to the satisfaction
    of the conditions set forth in Sections 2(E), 7 and 8, the closing of the
    purchase by the Investor of Shares (a "Closing") shall occur on the date
    which is no later than five (5) Trading Days following the applicable
    Put Notice Date (each a "Closing Date"). Within two (2) days of each
    Closing Date,(I) the Company shall deliver to the Investor pursuant to
    this Agreement, certificates representing the Shares to be issued to the
    Investor on such date and registered in the name of the Investor; and (II)
    the  Investor shall deliver to the Company the Purchase Price to be paid
    for such Shares, determined as set forth in Section 2(B). In lieu of
    delivering physical certificates representing the Securities and provided
    that the Company's transfer agent then is participating in The Depository
    Trust Company ("DTC") Fast Automated Securities Transfer ("FAST") program,
    upon request of the Investor, the Company shall use all commercially
    reasonable efforts to cause its transfer agent to electronically transmit
    the Securities by crediting the account of the Investor's prime broker
    (as specified by the Investor within a reasonably in advance of the
    Investor's notice) with DTC through its Deposit Withdrawal Agent
    Commission ("DWAC") system.

The Company understands that a delay in the issuance of Securities beyond
the Closing Date could result in economic damage to the Investor. After
the Effective Date, as compensation to the Investor for such loss, the
Company agrees to make late payments to the Investor for late issuance of
Securities (delivery of Securities after the applicable Closing Date) in
accordance with the following schedule (where "No. of Days Late" is defined
as the number of trading days beyond the Closing Date, with the Amounts
being cumulative.):

<PAGE>

LATE  PAYMENT  FOR  EACH
NO.  OF DAYS  LATE               $10,000 WORTH OF COMMON  STOCK

          1                                           $100
          2                                           $200
          3                                           $300
          4                                           $400
          5                                           $500
          6                                           $600
          7                                           $700
          8                                           $800
          9                                           $900
         10                                         $1,000
         Over 10                              $1,000 + $200 for each
                                        Business Day late beyond 10 days

The Company shall make any payments incurred under this Section in immediately
available funds upon demand by the Investor. Nothing herein shall limit the
Investor's right to pursue actual damages for the Company's failure to issue
and deliver the Securities to the Investor, except that such late payments
shall offset any such actual damages incurred by the Investor, and any Open
Market Adjustment Amount, as set forth below.

No other terms, rights or provisions of the Agreement are or should be
considered to have been modified by the terms of the Side Letter Agreement
and each party retains all other rights, obligations, privileges and duties
contained in the Agreement.

Agreed and Accepted on March 16, 2007:

Very truly yours,

Agreed to and Accepted on behalf of:

On the Go Healthcare, Inc.               Dutchess Private Equities Fund, Ltd.

/s/ Stuart Turk                          /s/ Douglas H. Leighton
------------------------------           -----------------------------------
Name                                     Name

CEO                                      Director
------------------------------           -----------------------------------
Title                                    Title

March 16, 2007                           March 16, 2007
------------------------------           -----------------------------------
Date                                     Date

<PAGE>Exhibit 10.11

    
      

    

    

      AMENDMENT
        TO LICENSE AGREEMENT

      

      

      Amendment
        to License Agreement by and between TheraCour Pharma, Inc., ("Theracour")
        as Licensor, and NanoViricides, Inc., (“Nano”) as Licensee.

      

      
        The
          License Grant in paragraph 2 is amended and restated as follows:

        

        1)
          License
          Grant. Theracour hereby grants to Nano a limited, non-transferable.
          exclusive
          license,
          subject to the provisions of paragraph 2.2 as amended
          below, for the manufacture, use, sale, or offer of sale of the Licensed
          Product( s) in the Territory.

        

        2)
          Paragraph
          2.1 of the said License Agreement is amended to include “Rabies Virus”.

        

        3) Paragraph
          2.2 of the said License Agreement is clarified, superseded, and replaced
          by the following paragraph:

        

        “TheraCour
          retains exclusive rights to develop and synthesize the different TheraCour
          base polymers used for making the various nanoviricides. A TheraCour base
          polymer
          is defined as a polymer that does not have the virus-specific ligand attached
          to
          it as yet and its structure is covered in one or more of the specified
          TheraCour
          patents. TheraCour
          also retains the exclusive rights to research and develop the chemistries
          for
attaching
          the virus-specific ligands to the base polymers. A “ligand” is defined herein as
a
          chemical or biological moiety that is capable of binding to some feature
          of the
          targeted virus
          particle, this enabling targeting to a specific strain, subtype, type or
          class
          of virus, or
          broad
          or multiple classes of viruses. A ligand itself may be a small chemical
          moiety,
          a peptide
          moiety, a fragment of any antibody, an RNA or DNA “aptamer”, or another
chemically
          defined structure. A TheraCour base polymer is also referred to herein
          as a
“nanomicelle”.
          A nanomicelle is thus a component element of the Licensed Products. Further,
          TheraCour agrees to identify, design, and develop ligand(s) necessary for
          the
development
          of the Licensed Products. As to any Licensed Product, TheraCour retains
          the
          initial exclusive right to develop and synthesize the nanomicelles exclusively
          for Nano.
          In
          the event that Theracour is unable to supply the quantities of the
          nanomicelle(s) required
          for manufacture of the Licensed Product(s), then upon notice and after
          any
applicable
          cure periods required under the License agreement, Nano can acquire the
          nanomicelle(s) from other third party providers.

      

       

      
        	
                NanoViricides,
                  Inc.

              	 	
                TheraCour
                  Pharma, Inc.

              
	 	 	 
	/s/
                Eugene Seymour	 	
                /s/
                  Leo Ehrlich

              
	
                By
                  Eugene Seymour, President

              	 	
                By
                  Leo Ehrlich, Vice PresidentExhibit 10.12

    
      

    

    
      	
              

            	
              *Nanotechhnology-Enabled
                Targeted Viricides"

            
	
              A
                Publicly Traded Company, "NNVC"

            
	
              www.nanoviricides.com

            

    

    

    

    Dec
      23,
      2005

    To

    Nguyen
      Tran
      Hien,
      MD, MPH, PhD

    Director

    National
      Institute of Hygiene and Epidemiology (NIHE)

    1
      Yersin
      Street

    Hanoi,
      Viet Nam

    

    Dear
      Dr.
      Hien:

    

    Enclosed
      please find a Memorandum of understanding between NanoViricides, Incorporated,
      USA, and NIHE, Viet Nam, as per our discussions for the purposes of cooperation
      between NanoViricides, Inc., and NIHE for novel nanotechnology-based
prevention
      strategies, therapies and diagnostics strategies for Influenza A subtype
      H5N1,

    

    We
      look
      forward to a fruitful cooperation in many areas.

    

    
      	 	
              Sincerely,

            	 
	 	
              /s/Anil
                R. Diwan

            	 
	 	
              Anil
                R. Diwan, Ph.D.

            	 
	 	
              President
                & Chairman

            	 
	 	
              NanoViricides,
                Inc.

            	 
	 	
              Mobile:
                203-606-9180

            	 
	 	
              email:
                adiwan@nanoviricides.com

            	 
	 	
              or
                adiwan@snet.net

            	 

    

     

    cc:

    Dang
      Duc
      Anh, PhD

    Vice
      Director, NIHE.

    

    

    135
      Wood
      Street, Ste. 205, West Haven, CT 06516, USA.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    Memorandum
      of Understanding

    Between

    NIHE,
      Viet Nam and NanoViricides, Inc., USA

    

    NANOVIRICIDES,
      INC. 135 Wood Street, Suite 205, West Haven, CT 06516, and National
      Institute of Hygiene and Epidemiology (NIHE), 1 Yersin Street, Hanoi, Viet
      Nam,
agree
      to
      enter into a scientific research cooperation on the development of
      prevention, diagnostics,
      and therapeutic strategies for Influenza A subtype H5N1, including:

    

      
        	 	
                *

              	
                Research
                  on Novel Nanotechnology-based Vaccines
                  (NanoVaccines),

              

      

      

      
        	 	
                *

              	
                Research
                  on Novel Nanotehnology-based Therapies (NanoViricides),
                  and

              

      

      

      
        	 	
                *

              	
                Research
                  on Novel Nanotechnology-based
                  Diagnostics,

              

      

    

    

    It
      Is
      understood that these development projects will begin as small
      projects. As success
      Is achieved, the projects can be continued for further development.

    

    These
      various strategies are based on the nanotechnology intellectual property and
      products
      of NanoViricides, Inc.

    

    NanoViricides,
      Inc. shall retain all intellectual property rights to
      resulting
      products and
      technologies and shall make full efforts for world-wide protection of such
      intellectual property
      rights.

    

    Certain
      rights for the new nanotechnology products and technologies develop shall
      be
      provided to NIHE for use in Viet Nam.

    

    The
      work
      plan, costs budget, compensation and financial responsibilities of each
party
      to
      the projects shall be determined in the final Agreement.

    

    It
      Is
      understood that both parties will be sharing confidential information and
intellectual
      property of the other party, and will ensure that such information is protected
      to
      its
      fullest and not publicly disclosed except by written consent from the other
      party when
      so
      decided.

    

    Signed:
      December 23, 2005 by both parties at NIHE, Hanoi, Viet Nam

    

    
      	
              /s/
                Nguyen Tran Hien

            	 	
              /s/
                Anil R. Diwan

            	 
	
              Professor
                Nguyen Tran Hien, MD, MPH, PhD

            	 	
              Anil
                R. Diwan, Ph.D.

            	 
	
              Director

            	 	
              President
                & Chairman

            	 
	
              National
                Institute of Hygiene and Epidemiology

            	 	
              Nanoviricides,
                Inc.

            	 
	
              1
                Yersin Street

            	 	
              135
                Wood Street, Ste. 205

            	 
	
              Hanoi,
                Viet Nam

            	 	
              West
                Haven, CT 06516, USA.

            	 

    

    

    Page
      1 of
      1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00119-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00119-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00119-of-00352.parquet"}]]